Compare Johnson & Johnson (JNJ) vs VICI Properties Inc (VICI) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

VICI Properties trades at $26.83, down 0.15% on the day, with technical indicators showing a neutral bias. The REIT maintains strong fundamentals with a 76.83% net income margin and consistent earnings beats in three of the last four quarters. Recent news highlights institutional buying interest and dividend sustainability discussions amid sector volatility.

VICI offers a compelling value proposition with a 6.7% dividend yield and 36% upside to the consensus price target of $30.00. Key risks include tenant concentration with Caesars/MGM accounting for 70% of rent and macroeconomic sensitivity. Wall Street remains bullish with 77% buy ratings supporting long-term income growth potential.